Literature DB >> 18521367

Bisphosphonate treatment of benign multifocal and unifocal osteolytic tumours of bone.

C L M H Gibbons1, M Petra, R Smith, N A Athanasou.   

Abstract

Growth of benign tumours and tumour-like lesions of bone results in osteolysis which may cause pathological fracture. Bisphosphonates are anti-osteolytic agents which have proved effective in the treatment of number of osteolytic conditions. In this study we report the results of treatment with the aminobisphosphonate, pamidronate, of three benign osteolytic tumours of bone, two cases of fibrous dysplasia and one of Langerhans cell histiocytosis. In all three cases there was clinical and radiological improvement following treatment. Radiologically, bone lesions did not exhibit progressive enlargement. Two cases of fibrous dysplasia also showed features suggestive of increased bone formation. These findings indicate that bisphosphonates are likely to be useful in controlling the osteolysis of benign tumours/tumour-like lesions of bone, particularly in those cases where surgical intervention is not possible or multifocal lesions are present.

Entities:  

Year:  2003        PMID: 18521367      PMCID: PMC2395513          DOI: 10.1080/1357714031000114165

Source DB:  PubMed          Journal:  Sarcoma        ISSN: 1357-714X


  17 in total

1.  Bisphosphonate therapy in fibrous dysplasia.

Authors:  J M Lane; S N Khan; W J O'Connor; M Nydick; J P Hommen; R Schneider; E Tomin; J Brand; J Curtin
Journal:  Clin Orthop Relat Res       Date:  2001-01       Impact factor: 4.176

2.  Experiences of clodronate treatment of multifocal eosinophilic granuloma of bone.

Authors:  I Elomaa; C Blomqvist; L Porkka; T Holmström
Journal:  J Intern Med       Date:  1989-01       Impact factor: 8.989

3.  Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures.

Authors:  M Nishikawa; T Akatsu; Y Katayama; Y Yasutomo; S Kado; N Kugal; M Yamamoto; N Nagata
Journal:  Bone       Date:  1996-01       Impact factor: 4.398

Review 4.  Cellular and molecular mechanisms of action of bisphosphonates.

Authors:  M J Rogers; S Gordon; H L Benford; F P Coxon; S P Luckman; J Monkkonen; J C Frith
Journal:  Cancer       Date:  2000-06-15       Impact factor: 6.860

5.  Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.

Authors:  R D Chapurlat; P D Delmas; D Liens; P J Meunier
Journal:  J Bone Miner Res       Date:  1997-10       Impact factor: 6.741

6.  Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma.

Authors:  N Abildgaard; J Rungby; H Glerup; K Brixen; M Kassem; H Brincker; L Heickendorff; E F Eriksen; J L Nielsen
Journal:  Eur J Haematol       Date:  1998-08       Impact factor: 2.997

7.  Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy.

Authors:  A Sauty; M Pecherstorfer; I Zimmer-Roth; P Fioroni; L Juillerat; M Markert; H Ludwig; P Leuenberger; P Burckhardt; D Thiebaud
Journal:  Bone       Date:  1996-02       Impact factor: 4.398

Review 8.  Bisphosphonates: a review of their pharmacokinetic properties.

Authors:  J H Lin
Journal:  Bone       Date:  1996-02       Impact factor: 4.398

9.  Central giant cell granulomas of the jaws regress with calcitonin therapy.

Authors:  M Harris
Journal:  Br J Oral Maxillofac Surg       Date:  1993-04       Impact factor: 1.651

10.  A system of staging musculoskeletal neoplasms.

Authors:  W F Enneking
Journal:  Clin Orthop Relat Res       Date:  1986-03       Impact factor: 4.176

View more
  5 in total

1.  Distinctive growth pattern in a patient with a delayed diagnosis of Langerhans' cell histiocytosis.

Authors:  Athanasios D Anastasilakis; Gregory A Kaltsas; Georgios Delimpasis; Ludwig Wilkens; George Kanakis; Polyzois Makras
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

2.  Neoadjuvant denosumab for the treatment of a sacral osteoblastoma.

Authors:  Jeremy J Reynolds; Dominique A Rothenfluh; Nick Athanasou; Shaun Wilson; David C Kieser
Journal:  Eur Spine J       Date:  2018-01-22       Impact factor: 3.134

3.  How Do Drugs Affect the Skeleton? Implications for Forensic Anthropology.

Authors:  Nicholas Márquez-Grant; Elisa Baldini; Victoria Jeynes; Lucie Biehler-Gomez; Layla Aoukhiyad; Nicholas V Passalacqua; Gaia Giordano; Domenico Di Candia; Cristina Cattaneo
Journal:  Biology (Basel)       Date:  2022-03-29

4.  Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone.

Authors:  Maurice Balke; Laura Campanacci; Carsten Gebert; Piero Picci; Max Gibbons; Richard Taylor; Pancras Hogendoorn; Judith Kroep; John Wass; Nicholas Athanasou
Journal:  BMC Cancer       Date:  2010-08-29       Impact factor: 4.430

Review 5.  Clinical and translational pharmacological aspects of the management of fibrous dysplasia of bone.

Authors:  Marlous Rotman; Neveen Agnes Therese Hamdy; Natasha M Appelman-Dijkstra
Journal:  Br J Clin Pharmacol       Date:  2018-12-25       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.